PRESS RELEASE published on 04/07/2026 at 18:59, 5 months 3 days ago Informations privilégiées / Communiqué sur comptes, résultats GenSight Biologics publie sa situation de trésorerie et les revenus du programme d’Autorisation d’Accès Compassionnel (AAC) au 31 mars 2026. La trésorerie s'élevait à 3,2 millions d’euros avec des revenus de 2,6 millions d’euros Trésorerie Revenus Thérapie Génique GenSight Biologics Programme AAC
PRESS RELEASE published on 04/07/2026 at 18:59, 5 months 3 days ago Inside Information / News release on accounts, results GenSight Biologics reports cash position and revenue from early access program as of March 31, 2026. Operating cash burn, fundraising, and treatment proceeds highlighted Revenue Fundraising Cash Position GenSight Biologics Early Access Program
BRIEF published on 03/27/2026 at 07:35, 5 months 14 days ago GenSight Biologics publie ses résultats financiers pour 2025 Activités De Financement Cash Runway Dépenses De R&D Résultats Financiers 2025 Étapes Réglementaires
BRIEF published on 03/27/2026 at 07:35, 5 months 14 days ago GenSight Biologics Reports 2025 Financial Performance Financing Activities Cash Runway R&D Expenses Regulatory Milestones Financial Results 2025
PRESS RELEASE published on 03/27/2026 at 07:30, 5 months 14 days ago Informations privilégiées / Communiqué sur comptes, résultats GenSight Biologics publie ses résultats financiers consolidés estimés pour l'année 2025, marquée par des avancées réglementaires et une extension de l'horizon de trésorerie jusqu'en décembre 2026 Résultats Financiers 2025 GenSight Biologics Horizon De Trésorerie Avancées Réglementaires
PRESS RELEASE published on 03/27/2026 at 07:30, 5 months 14 days ago Inside Information / News release on accounts, results GenSight Biologics reported estimated full-year consolidated financial results for 2025, highlighting key regulatory milestones achieved and cash runway projection through December 2026 Financial Results Phase III Trial GenSight Biologics Cash Runway Regulatory Milestones
BRIEF published on 03/23/2026 at 09:53, 5 months 18 days ago Heights Capital Management dépasse 8% du capital de GENSIGHT BIOLOGICS Franchissement De Seuil Augmentation De Capital GenSight Biologics Capital Et Droits De Vote Heights Capital
BRIEF published on 03/23/2026 at 09:53, 5 months 18 days ago Heights Capital Management exceeds 8% of GENSIGHT BIOLOGICS' capital Capital Increase Threshold Crossing GenSight Biologics Capital And Voting Rights Heights Capital
PRESS RELEASE published on 03/23/2026 at 09:48, 5 months 18 days ago Franchissement de seuils Déclaration de franchissement de seuils par Heights Capital Management pour le compte de CVI Investments, Inc. concernant GENSIGHT BIOLOGICS S.A. publiée le 17 mars 2026 Déclaration Franchissement De Seuils Heights Capital Management Gensight Biologics S.A. CVI Investments
BRIEF published on 03/18/2026 at 10:20, 5 months 23 days ago GenSight Biologics finalise sa levée de fonds de 1,7 million d'euros Actions Ordinaires Levée De Fonds GenSight Biologics Thérapies Géniques Facteurs De Risque
Published on 09/10/2026 at 22:25, 3 hours 50 minutes ago Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 15:20, 10 hours 55 minutes ago MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 11 hours 15 minutes ago All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
Published on 09/10/2026 at 14:37, 11 hours 38 minutes ago Worksport (NASDAQ:WKSP) Invites Shareholders to September 15 CEO Town Hall
Published on 09/11/2026 at 00:05, 2 hours 10 minutes ago Club Offers for Travel Enthusiasts in Germany
Published on 09/11/2026 at 00:01, 2 hours 14 minutes ago Club Offers for Travel Enthusiasts in Germany
Published on 09/10/2026 at 22:39, 3 hours 35 minutes ago EQS-Adhoc: Notice by Rumble Deutschland AG regarding an upcoming squeeze-out under German Stock Corporation Law
Published on 09/10/2026 at 22:10, 4 hours 4 minutes ago flatexDEGIRO with changes to the Supervisory Board
Published on 09/10/2026 at 22:07, 4 hours 8 minutes ago EQS-Adhoc: flatexDEGIRO SE: Changes to the Supervisory Board
Published on 09/10/2026 at 19:30, 6 hours 45 minutes ago Availability of the 2026 Interim Financial Report
Published on 09/10/2026 at 19:30, 6 hours 45 minutes ago Mise à disposition du Rapport Financier Semestriel 2026
Published on 09/10/2026 at 18:10, 8 hours 5 minutes ago LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 août 2026
Published on 09/10/2026 at 17:45, 8 hours 30 minutes ago COGRA : RÉSULTATS ANNUELS 2025/26 - Retour à la croissance rentable et structure financière renforcée
Published on 09/10/2026 at 17:42, 8 hours 32 minutes ago Déclaration d'actions et de droits de vote au 31.08.2026
